donanemab

An experimental Alzheimer's drug, diranersen, developed by Biogen, shows potential to slow cognitive decline by reducing tau protein levels, a key contributor to the disease. Early study results suggest it may offer benefits comparable to existing amyloid-targeting therapies, though further large-scale trials are needed to confirm efficacy.